Mustang Bio Inc MBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MBIO is a good fit for your portfolio.
News
-
Mustang Bio Announces Pricing of $4 Million Public Offering
-
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
-
Mustang Bio Shares Down 12% After Direct Offering Prices
-
Mustang Bio Shares Rise 13% After FDA Acceptance of IND Application
-
Mustang Bio Gets FDA Acceptance of IND Application for MB-109 Cancer Treatment
Trading Information
- Previous Close Price
- $0.32
- Day Range
- $0.22–0.33
- 52-Week Range
- $0.22–8.17
- Bid/Ask
- $0.25 / $0.28
- Market Cap
- $2.46 Mil
- Volume/Avg
- 735,080 / 234,576
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 80
- Website
- https://www.mustangbio.com
Comparables
Valuation
|
Metric
|
MBIO
|
SWTX
|
KPTI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 17.77 | 5.45 | — |
Price/Sales | — | 538.29 | 0.86 |
Price/Cash Flow | — | — | — |
Price/Earnings
MBIO
SWTX
KPTI
Financial Strength
|
Metric
|
MBIO
|
SWTX
|
KPTI
|
|---|---|---|---|
Quick Ratio | 0.66 | 6.21 | 3.14 |
Current Ratio | 0.74 | 6.41 | 3.37 |
Interest Coverage | −38.92 | — | −5.45 |
Quick Ratio
MBIO
SWTX
KPTI
Profitability
|
Metric
|
MBIO
|
SWTX
|
KPTI
|
|---|---|---|---|
Return on Assets (Normalized) | −106.47% | −39.61% | −42.20% |
Return on Equity (Normalized) | −264.57% | −45.43% | — |
Return on Invested Capital (Normalized) | −149.65% | −49.28% | −111.18% |
Return on Assets
MBIO
SWTX
KPTI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pdbfjkwrp | Svplw | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qdtqywptg | Qtcgtg | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cbtgbzhm | Dyktk | $97.3 Bil | |
MRNA
| Moderna Inc | Wtvnbjldx | Pxxb | $42.7 Bil | |
ARGX
| argenx SE ADR | Fdqplsnkl | Gdyw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Tshkgzzh | Ftfhk | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Psvmtwlkt | Xbwqvkp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Grskfqhj | Vckvrc | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rgfwhymr | Bvrnzqb | $12.6 Bil | |
INCY
| Incyte Corp | Vjjwjynj | Hqwrq | $11.8 Bil |